Gender Has No Effect on Interferon-Beta Response in MS
the Neurology Advisor take:
Gender does not seem to have an effect on response to interferon-beta treatment in men and women with multiple sclerosis (MS), according to a study published in Acta Neurologica Scandinavica.
Researchers hypothesized that gender played a role in the relapse rate of patients with MS being treated with interferon-beta. They studied 2,033 patients treated with the therapy from 1996 to 2003, and determined neutralizing antibody (Nab)-positive and Nab-negative periods in each patient using Nab tests. Relapse rates were compared between NAb-postive and NAb-negative periods, with patients serving as their own controls.
Using relapse counts as the response variable, researchers found that NAbs had a strong influence in the on-treatment relapse rates in both sexes, but the rates did not differ between men and women. The women:men relapse rate ratio irrespective of NAb status was 1.47 (95%CI; 1.28–1.68).
The researchers concluded that there was no indication of differing effects of interferon-beta usage in men or women.
This study intends to identify a relationship between gender and effectiveness of interferon-beta treatment in patients with multiple sclerosis. The study of over 2,000 patients treated with the therapy based response rates on NAb-postive and NAb-negative periods within each patient, with relapse counts as the response variable. No correlation between sex and relapse rate during treatment with interferon-beta was found.
Next Article in Multiple Sclerosis
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd